Cargando…
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
INTRODUCTION: Despite some of the oncogenic driver mutations that have been associated with increased expression of programmed death-ligand 1 (PD-L1), the correlation between PD-L1 expression and ROS1 fusion in NSCLC cells, especially for those with Crizotinib resistance has not been fully addressed...
Autores principales: | Liu, Zheng, Zhao, Kejia, Wei, Shiyou, Liu, Chengwu, Zhou, Jiankang, Gou, Qiheng, Wu, Xia, Yang, Zhenyu, Yang, Yanbo, Peng, Yong, Cheng, Qing, Liu, Lunxu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458663/ https://www.ncbi.nlm.nih.gov/pubmed/32923114 http://dx.doi.org/10.1080/2162402X.2020.1758003 |
Ejemplares similares
-
Tumor-Infiltrating PD-1(hi)CD8(+)-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
por: Yang, Zhenyu, et al.
Publicado: (2021) -
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma
por: Leng, Xuefeng, et al.
Publicado: (2021) -
PD‐L1/PD‐L1 signalling promotes colorectal cancer cell migration ability through RAS/MEK/ERK
por: Cao, Yihui, et al.
Publicado: (2022) -
What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
por: Cui, Ruichen, et al.
Publicado: (2022) -
Thoracoscopic tracheal reconstruction without surgical field intubation
por: Zhao, Kejia, et al.
Publicado: (2016)